(c) 2024 PillSync.com

Vigabatrin 500 MG Oral Tablet

1 INDICATIONS AND USAGE Vigabatrin tablets are indicated for the treatment of: Refractory Complex Partial Seizures as adjunctive therapy in patients 2 years of age and older who have responded inadequately to several alternative treatments; Vigabatrin tablets are not indicated as a first line agent ( 1.1 ) 1.1 Refractory Complex Partial Seizures (CPS) Vigabatrin tablets are indicated as adjunctive therapy for adults and pediatric patients 2 years of age and older with refractory complex partial seizures who have inadequately responded to several alternative treatments and for whom the potential benefits outweigh the risk of vision loss [see Warnings and Precautions (5.1) ] . Vigabatrin tablets are not indicated as a first line agent for complex partial seizures.

actavis pharma, inc.


4 years ago OVAL WHITE A314 Vigabatrin 500 MG Oral Tablet

OVAL WHITE A314

16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied

VIGABATRIN Tablets, USP are available for oral administration and are supplied as follows: 500 mg — Each white to off-white, film-coated, oval biconvex tablet functionally-scored on one side and debossed with A314 on the other side contains 500 mg of

VIGABATRIN, USP. Tablets are supplied in bottles of 100 (NDC 0591-3851-01). 16.2 Storage and Handling Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature]. Dispense in a tight, light-resistant container with a child-resistant closure. Keep this and all drugs out of the reach of children.


More pills like OVAL A314












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site